Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Nurix Therapeutics, Inc. Stock Research

NRIX

8.85USD-0.19(-2.10%)Market Closed
Watchlist

Market Summary

USD8.85-0.19
Market Closed
-2.10%

NRIX Stock Price

NRIX RSI Chart

NRIX Valuation

Market Cap

421.5M

Price/Earnings (Trailing)

-2.68

Price/Sales (Trailing)

6.92

EV/EBITDA

-2.77

Price/Free Cashflow

-2.63

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-466.93%

Return on Equity

-65.16%

Return on Assets

-48.24%

Free Cashflow Yield

-38.08%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

60.9M

Revenue Y/Y

168.33%

Revenue Q/Q

141.83%

NRIX Earnings

Earnings (TTM)

-157.4M

Earnings Y/Y

46.53%

Earnings Q/Q

40.4%

Price Action

52 Week Range

8.2215.09
(Low)(High)

Last 7 days

-0.1%

Last 30 days

3.3%

Last 90 days

-11.6%

Trailing 12 Months

-30.9%

NRIX Financial Health

Current Ratio

4.44

NRIX Investor Care

Shares Dilution (1Y)

6.09%

Diluted EPS (TTM)

-2.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for NRIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-07-31
van Houte Hans
sold
-12,020
9.6547
-1,245
chief financial officer
2023-07-31
Ring Christine
sold
-13,709
9.6547
-1,420
general counsel
2023-07-31
Hansen Gwenn
sold
-18,189
9.6547
-1,884
chief scientific officer
2023-07-30
Hansen Gwenn
acquired
-
-
5,207
chief scientific officer
2023-07-30
Ring Christine
acquired
-
-
3,924
general counsel
2023-07-30
van Houte Hans
acquired
-
-
4,886
chief financial officer
2023-05-01
Wolff Stefani
sold
-3,377
9.8763
-342
evp and coo
2023-05-01
Ring Christine
sold
-6,735
9.8763
-682
general counsel
2023-05-01
Hansen Gwenn
sold
-11,219
9.8763
-1,136
chief scientific officer
2023-05-01
van Houte Hans
sold
-7,120
9.8763
-721
chief financial officer

1–10 of 50

Which funds bought or sold NRIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-4.37
48,000
690,000
-%
2023-09-06
Deep Track Capital, LP
unchanged
-
3,327,590
29,948,300
1.39%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
5.68
81,062
510,099
-%
2023-08-21
Affinity Asset Advisors, LLC
reduced
-33.33
-333,000
999,000
0.35%
2023-08-16
Nuveen Asset Management, LLC
reduced
-0.38
717,496
6,667,500
-%
2023-08-15
GOLDMAN SACHS GROUP INC
reduced
-40.33
-1,578,250
3,223,250
-%
2023-08-15
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-6.00
47,000
859,000
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
19.69
102,872
399,730
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
200
61,000
86,000
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
234
891,041
1,213,380
-%

1–10 of 48

Latest Funds Activity

Are funds buying NRIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NRIX
No. of Funds

Schedule 13G FIlings of Nurix Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 24, 2023
deep track capital, lp
5.75%
2,717,171
SC 13G
Feb 14, 2023
third rock ventures iii, l.p.
0%
0
SC 13G/A
Feb 14, 2023
deep track capital, lp
4.81%
2,266,569
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
6.9%
3,253,736
SC 13G/A
Feb 14, 2023
redmile group, llc
9.9%
4,899,772
SC 13G/A
Feb 14, 2023
baker bros. advisors lp
9.99%
4,801,954
SC 13G/A
Feb 08, 2023
wasatch advisors inc
-
0
SC 13G
Jan 25, 2023
blackrock inc.
8.8%
4,142,528
SC 13G/A
Jun 10, 2022
deep track capital, lp
5.19%
2,436,164
SC 13G
Feb 14, 2022
third rock ventures iii, l.p.
5.4%
2,422,549
SC 13G/A

Recent SEC filings of Nurix Therapeutics

View All Filings
Date Filed Form Type Document
Sep 07, 2023
8-K
Current Report
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Aug 01, 2023
4
Insider Trading
Jul 13, 2023
8-K
Current Report
Jul 13, 2023
10-Q
Quarterly Report

Peers (Alternatives to Nurix Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.7T
383.9B
-3.49% 14.63%
28.86
7.12
-0.93% -4.89%
2.4T
211.9B
-3.06% 31.92%
32.56
11.12
6.88% -0.52%
1.7T
289.5B
-1.47% 30.51%
27.19
5.72
4.10% -15.36%
1.3T
538.0B
-4.72% 10.07%
101.87
2.47
10.73% 12.62%
MID-CAP
1.5B
9.9B
-28.14% -36.34%
55.75
0.15
24.14% 106.11%
795.7M
246.5M
-4.07% -6.47%
-5.01
3.23
6.65% -174.04%
SMALL-CAP
1.6B
627.1M
-7.75% -14.29%
-1.08
2.51
-0.20% -204.67%
1.5B
2.2B
-10.06% 7.70%
11.01
0.71
38.20% -10.10%
1.0B
543.3M
-3.23% 5.22%
-715.94
1.91
31.74% 78.13%
961.6M
56.2M
-5.30% -69.36%
-1.14
17.12
40.31% -12.26%
614.9M
356.8M
-16.65% -37.31%
-2.19
1.72
-23.03% 15.53%
507.0M
1.0B
-15.90% -35.94%
-19.18
0.49
-11.34% -107.10%
462.3M
453.3M
100.98% -69.12%
-0.38
1.02
-16.04% 55.90%
104.1M
13.7M
-12.49% -77.75%
-0.62
7.62
413.65% 52.51%

Nurix Therapeutics News

Nasdaq
Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving ....
Nasdaq,
3 days ago
Clayton County Register
InvestorsObserver
Investing.com UK
Seeking Alpha
Icosavax GAAP EPS of -$0.59.
Seeking Alpha,
39 days ago
Seeking Alpha
Seeking Alpha

Returns for NRIX

Cumulative Returns on NRIX

-33.9%


3-Year Cumulative Returns

Risks for NRIX

What is the probability of a big loss on NRIX?

94.0%


Probability that Nurix Therapeutics stock will be more than 20% underwater in next one year

91.0%


Probability that Nurix Therapeutics stock will be more than 30% underwater in next one year.

75.3%


Probability that Nurix Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NRIX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Nurix Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue46.2%60,935,00041,691,00038,627,00039,240,00038,701,00034,360,00029,750,00029,043,00022,876,00019,967,00017,820,00012,993,00019,488,00024,745,00031,115,00039,004,00037,346,00036,936,000
Operating Expenses0.1%226,060,000225,766,000222,494,000212,370,000194,110,000170,468,000147,636,000128,984,000113,012,00096,919,00082,803,00071,532,00061,447,00058,713,33353,351,00052,768,000--
  S&GA Expenses5.2%40,614,00038,590,00037,997,00037,448,00036,043,00033,900,00031,202,00028,636,00024,631,00020,390,00016,309,00012,660,00010,506,0009,648,0008,326,0008,736,000--
  R&D Expenses-0.9%185,446,000187,176,000184,497,000174,922,000158,067,000136,568,000116,434,000100,348,00088,381,00076,529,00066,494,00058,872,00050,941,00049,065,33345,025,00044,032,000--
EBITDA----175,011,000-166,734,000-150,793,000-132,335,000-114,273,000-96,655,000-86,314,000-73,178,000-61,597,000-55,073,000-38,973,000-35,288,000-19,106,000-7,268,000--
EBITDA Margin----4.53-4.25-3.90-3.85-3.84-3.33-3.77-3.66-3.46-4.24-2.00-1.43-0.61-0.19--
Earnings Before Taxes----180,360,000-171,301,000-154,550,000-135,392,000-117,063,000-99,278,000-88,837,000-75,601,000-63,777,000-57,213,000-41,113,000-37,474,666-21,460,000-9,668,000--
EBT Margin----4.67-4.37-3.99-3.94-3.93-3.42-3.88-3.79-3.58-4.40-2.11-1.51-0.69-0.25--
Net Income11.8%-157,436,000-178,560,000-180,360,000-171,345,000-154,471,000-135,452,000-117,194,000-99,406,000-89,088,000-55,126,000-43,242,000-36,847,000-20,757,000-31,405,000-21,699,000-10,906,666-11,506,000-10,740,000
Net Income Margin100.0%--4.28-4.67-4.37-3.99-3.94-3.94-3.42-3.89-2.76-2.43-2.84-1.07-1.27-0.70-0.28-0.31-0.29
Free Cashflow100.0%--176,678,000-172,051,000-163,304,000-145,450,000-143,373,000-90,061,000-79,641,000-55,615,000-38,031,000-4,633,0003,054,00014,486,66753,814,000-1,050,00016,868,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-5.3%35137041745939443847749351839739641244.00
  Current Assets0.6%29028831835530728031135839631129836439.00
    Cash Equivalents75.6%59.0034.0064.0048.0042.0079.0081.0014718812611926635.00
  Net PPE4.4%18.0018.0017.0017.0016.0014.0011.0010.008.007.007.007.004.00
Liabilities-5.6%91.0096.0011311712813213411812012710610454.00
  Current Liabilities11.4%72.0065.0071.0068.0073.0066.0066.0051.0047.0048.0045.0041.0016.00
Shareholder's Equity-5.2%260274304343267306342375398270290308-
  Retained Earnings-5.5%-466-441-401-354-308-263-220-183-154-127-103-83.78-60.46
  Additional Paid-In Capital1.2%7287197097015795715645585523983943913.00
Shares Outstanding0.4%48.0047.0047.0047.0045.0045.0045.0044.0044.0039.0039.008.003.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations8.7%-151-165-159-152-136-135-84.36-73.94-50.10-33.00-0.088.0018.0056.001.0018.00
  Share Based Compensation6.4%32.0031.0028.0025.0022.0019.0016.0013.0010.007.004.002.001.001.001.000.00
Cashflow From Investing1502.2%52.003.0027.00-64.33-13.49-65.83-108-196-292-237-254-134-34.83-47.588.0017.00
Cashflow From Financing-0.3%1171171171184.001541541523713403393401600.000.000.00

NRIX Income Statement

2023-05-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
May 31, 2023
May 31, 2022
May 31, 2023
May 31, 2022
Total revenue$ 30,676$ 11,432$ 43,361$ 21,053
Operating expenses:    
Research and development45,76347,49391,57990,630
General and administrative11,6789,65421,49918,882
Total operating expenses57,44157,147113,078109,512
Loss from operations(26,765)(45,715)(69,717)(88,459)
Interest and other income, net2,4883144,707525
Net loss$ (24,277)$ (45,401)$ (65,010)$ (87,934)
Net loss per share, basic (in USD per share)$ (0.45)$ (1.01)$ (1.20)$ (1.96)
Net loss per share, diluted (in USD per share)$ (0.45)$ (1.01)$ (1.20)$ (1.96)
Weighted-average number of shares outstanding, basic (in shares)54,259,04544,898,40954,144,90944,797,235
Weighted-average number of shares outstanding, diluted (in shares)54,259,04544,898,40954,144,90944,797,235
Collaboration revenue    
Total revenue$ 10,676$ 11,432$ 23,361$ 21,053
License revenue    
Total revenue$ 20,000$ 0$ 20,000$ 0

NRIX Balance Sheet

2023-05-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
May 31, 2023
Nov. 30, 2022
Current assets:  
Cash and cash equivalents$ 58,958$ 64,474
Marketable securities, current222,219244,667
Prepaid expenses and other current assets8,8379,308
Total current assets290,014318,449
Marketable securities, non‑current27,46363,879
Operating lease right-of-use assets9,94112,345
Property and equipment, net18,49517,163
Restricted cash901901
Other assets3,8104,022
Total assets350,624416,759
Current liabilities:  
Accounts payable4,5255,064
Accrued expenses and other current liabilities18,09122,428
Operating lease liabilities, current5,5835,530
Deferred revenue, current44,06337,633
Total current liabilities72,26270,655
Operating lease liabilities, net of current portion3,7586,434
Deferred revenue, net of current portion14,68335,974
Total liabilities90,703113,063
Commitments and contingencies (Note 6)
Stockholdersʼ equity:  
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2023 and November 30, 2022; no shares issued and outstanding as of May 31, 2023 and November 30, 202200
Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2023 and November 30, 2022; 47,631,208 and 47,172,299 shares issued and outstanding as of May 31, 2023 and November 30, 2022, respectively4847
Additional paid-in capital728,038709,220
Accumulated other comprehensive loss(1,903)(4,319)
Accumulated deficit(466,262)(401,252)
Total stockholdersʼ equity259,921303,696
Total liabilities and stockholdersʼ equity$ 350,624$ 416,759
Arthur T. Sands
240
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.